FDA rejects Capricor's cell therapy for Duchenne cardiomyopathy, citing insufficient evidence, but the company plans to resubmit with new trial data.
OpenAI's $3 billion bid for Windsurf fails, leading Google to swiftly hire Windsurf's top talent for its DeepMind division, highlighting the intensifying race among tech giants to acquire AI expertise.
FDA rejects Capricor's cell therapy for Duchenne cardiomyopathy, citing insufficient evidence, but the company plans to resubmit with new trial data.
OpenAI's $3 billion bid for Windsurf fails, leading Google to swiftly hire Windsurf's top talent for its DeepMind division, highlighting the intensifying race among tech giants to acquire AI expertise.